This company listing is no longer active
ONCT Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Oncternal Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.53 |
| 52 Week High | US$13.14 |
| 52 Week Low | US$0.53 |
| Beta | 1.2 |
| 1 Month Change | -64.42% |
| 3 Month Change | -86.90% |
| 1 Year Change | -93.09% |
| 3 Year Change | -99.12% |
| 5 Year Change | -99.43% |
| Change since IPO | -99.63% |
Recent News & Updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Shareholder Returns
| ONCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -29.5% | 3.7% | 1.2% |
| 1Y | -93.1% | -1.0% | 23.7% |
Return vs Industry: ONCT underperformed the US Biotechs industry which returned 15% over the past year.
Return vs Market: ONCT underperformed the US Market which returned 32.2% over the past year.
Price Volatility
| ONCT volatility | |
|---|---|
| ONCT Average Weekly Movement | 28.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ONCT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ONCT's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 29 | Jim Breitmeyer | www.oncternal.com |
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Oncternal Therapeutics, Inc. Fundamentals Summary
| ONCT fundamental statistics | |
|---|---|
| Market cap | US$1.56m |
| Earnings (TTM) | -US$34.57m |
| Revenue (TTM) | US$2.16m |
0.7x
P/S Ratio0.0x
P/E RatioIs ONCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCT income statement (TTM) | |
|---|---|
| Revenue | US$2.16m |
| Cost of Revenue | US$25.09m |
| Gross Profit | -US$22.93m |
| Other Expenses | US$11.65m |
| Earnings | -US$34.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.68 |
| Gross Margin | -1,060.99% |
| Net Profit Margin | -1,599.95% |
| Debt/Equity Ratio | 0% |
How did ONCT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/04 01:46 |
| End of Day Share Price | 2024/12/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncternal Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kaveri Pohlman | BTIG |
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Carl Byrnes | Northland Capital Markets |